This phase I trial is trying to determine the safety and effectiveness of two drugs (Ceritinib and Nivolumab), in the treatment of ALK + Non-Small Cell (NSC) Lung Cancer.
This trial is treating patients with Non-Small Cell (NSC) Lung Cancer (ALK+).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
Recruiting Hospitals Read More